![](/wp-content/uploads/2022/01/Jan-18-2022-Blast-Cover.png)
$599
Lilly Partners with Abbisko Therapeutics and Evotec; Novo Partners with EraCal Therapeutic; Fractyl Announces Initial Interim Feasibility Data
A series of cardiometabolic-related news items have been observed: Abbisko Therapeutics announced it has entered into a worldwide collaboration and exclusive licensing agreement with Lilly for the development of novel cardiometabolic therapies; Evotec announced a three-year drug discovery collaboration with Lilly for metabolic diseases focusing on kidney diseases and diabetes; EraCal Therapeutics announced a research collaboration with Novo Nordisk for development of anti-obesity pharmacotherapy; and Fractyl Health announced initial interim feasibility data from its open-label REVITA-T2Di trial. Below, FENIX provides highlights and insights for the respective new items.